Gene therapy using adenoviral vector encoding 4-1BBIg gene significantly prolonged murine cardiac allograft survival
- 31 August 2006
- journal article
- Published by Elsevier in Transplant Immunology
- Vol. 16 (2) , 88-94
- https://doi.org/10.1016/j.trim.2006.03.010
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Interfacing T-cell effector and regulatory function through CD137 (4-1BB) co-stimulationTrends in Immunology, 2005
- Induction of a Th2 immune response by co-administration of recombinant adenovirus vectors encoding amyloid β-protein and GM-CSFVaccine, 2005
- Anti-CD154 mAb Treatment But Not Recipient CD154 Deficiency Leads to Long-Term Survival of Xenogeneic Islet GraftsAmerican Journal of Transplantation, 2005
- Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survivalTransplant International, 2004
- Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40Nature Reviews Immunology, 2004
- Long-term acceptance of rat cardiac allografts on the basis of adenovirus mediated CD40Ig plus CTLA4Ig gene therapiesTransplantation, 2003
- Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?Nature Reviews Immunology, 2003
- Involvement of tumor necrosis factor receptor superfamily (TNFRSF) members in the pathogenesis of inflammatory diseasesExperimental & Molecular Medicine, 2003
- The B7–CD28 superfamilyNature Reviews Immunology, 2002
- QUANTIFICATION OF MURINE CYTOKINE mRNAs USING REAL TIME QUANTITATIVE REVERSE TRANSCRIPTASE PCRCytokine, 1999